oleksandr-halushchak-shutterstock-com

OLEKSANDR HALUSHCHAK / SHUTTERSTOCK.COM

10 October 2016Biotechnology

A woolly debate: the rights and wrongs of cloning

“Should life be patented?” asks Paul Chapman, head of Avidity’s life sciences team, relaying the concern of the UK public and intellectual property officials when the creators of Dolly the Sheep sought to patent their experiment.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Life sciences leaders recognised at LSPN Awards USA 2025

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

Novartis settles with licensee of blood cancer therapy day before trial